Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
ER-positive breast cancer patients do not usually respond to immunotherapy. In this phase II clinical trial, the authors report the safety and efficacy of combining vorinostat and pembrolizumab with tamoxifen in ER-positive breast cancers and provide evidence that T-cell exhaustion may serve as a po...
Guardado en:
Autores principales: | Manuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, Mark Moasser, Amy J. Chien, Michelle E. Melisko, Hope Rugo, Roshun Rahimi, Travis Deal, Adil Daud, Michael D. Rosenblum, Scott Thomas, Pamela N. Munster |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
por: Neelima Vidula, et al.
Publicado: (2021) -
Transcriptional suppression of CD8+ T cell exhaustion for improving T cell immunotherapy
por: Xue Yang, et al.
Publicado: (2021) -
Immunotherapy in breast cancer: A clinician's perspective
por: Sibapriya Chaudhuri, et al.
Publicado: (2021) -
The Reforms in Russia: Exhausting Running on the Spot
por: Vyacheslav Veniaminovich Kruglov, et al.
Publicado: (2018) -
Zoom Exhaustion & Fatigue Scale
por: G. Fauville, et al.
Publicado: (2021)